Objective : Although prior meta-analyses have significantly enriched the available literature
on the comorbidity of substance use disorders (SUD) among individuals with eating …

Importance Cannabis withdrawal syndrome (CWS)—a diagnostic indicator of cannabis use
disorder—commonly occurs on cessation of heavy and prolonged cannabis use. To date, the …

Background Ketamine appears to have a therapeutic role in certain mental disorders, most
notably depression. However, the comparative performance of different formulations of …

Objective We investigated the comparative efficacy and tolerability of pharmacological
treatment strategies for the treatment of acute bipolar depression. Data sources A systematic …

Background: Successful treatment of major depressive disorder (MDD) can be challenging,
and failures ("treatment-resistant depression" [TRD]) are frequent. Steps to address TRD …

The legality, recreational and medical use of cannabis varies widely by country and region
but remains largely prohibited internationally. In October 2018, Canada legalized the …

Background Racemic ketamine and esketamine have demonstrated rapid antidepressant
effects. We aimed to review the efficacy and safety of racemic and esketamine for depression. …

Background Posttraumatic stress disorder (PTSD) is a common psychiatric condition that can
develop following a traumatic experience. PTSD is associated with significant disability, a …

Background Intranasal esketamine has received regulatory approvals for the treatment of
depression. Recently a large trial of repeated dose racemic ketamine also demonstrated …

Introduction Polypharmacy is commonly associated with adverse health outcomes. There
are currently no meta-analyses of the prevalence of polypharmacy or factors associated with …